Pharmaceuticals news FT.com

23andMe sale grafts a happy ending on to a glum tale

Being spliced on to Regeneron will free the genetic testing company from its fatal dependence on sporadic revenue

May 20, 2025 - 16:15
 0
23andMe sale grafts a happy ending on to a glum tale
Being spliced on to Regeneron will free the genetic testing company from its fatal dependence on sporadic revenue
Read More

Tags:

Previous Article

Pfizer buys into PD-1/VEGF competition with 3SBio deal

Next Article

STAT+: FDA will limit Covid vaccines to people over 65 or at high risk of seriou...

Related Posts

Trump seeks to lower US drugs prices with tariff threat to Europe

Trump seeks to lower US drugs prices with tariff threat...

May 12, 2025  0

Trump urged to target ‘lazy patent expansion’ in US drug bill push

Trump urged to target ‘lazy patent expansion’ in US dru...

May 20, 2025  0

How Hims & Hers survived the great Spac shakeout

How Hims & Hers survived the great Spac shakeout

May 13, 2025  0